Lanreotide Autogel for persistent diabetic macular edema.
Diffuse diabetic macular edema is usually refractory to conventional treatment. We investigated the effectiveness of a new prolonged lanreotide formulation in patients with bad-controlled diabetes and persistent cystoid macular edema. Our findings suggest that monthly subcutaneous injections of lanreotide Autogel offered an effective treatment alternative in these patients.
Hernaez-Ortega
Maria C
MC
European Innovative Biomedicine Institute (EIBI), Cantabria, Spain. concha.hernaez@eibi.es
Soto-Pedre
Enrique
E
Piniés
José A
JA
D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D003925:Diabetic Angiopathies / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005260:Female; D005584:Fovea Centralis / Q000473:pathology; D005782:Gels; D006801:Humans; D007267:Injections; D008269:Macular Edema / Q000188:drug therapy*; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000008:administration & dosage / Q000627:therapeutic use*; D011788:Quality of Life; D013004:Somatostatin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014792:Visual Acuity
D005782:Gels; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin